MedPath

Tagged News

Caris Life Sciences Files for $300 Million IPO to Advance AI-Powered Precision Oncology Platform

Precision MedicineAIOncology
  • Caris Life Sciences has filed for an initial public offering aiming to raise up to $300 million, with plans to list on Nasdaq under the ticker symbol "CAI".
  • The company has developed an AI-powered precision medicine platform for oncology, built on a massive dataset of over 6.5 million tests from 849,000 cases, generating measurements of more than 38 billion molecular markers.
  • Caris' commercial portfolio includes MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a blood-based profiling solution launched in Q1 2024 for therapy selection.

Insilico Medicine Develops AI-Designed ENPP1 Inhibitor ISM5939 for Cancer Immunotherapy

AIDrug Discovery
  • Insilico Medicine used generative AI platforms PandaOmics and Chemistry42 to discover and design ISM5939, a highly selective oral ENPP1 inhibitor that modulates the STING pathway for cancer immunotherapy.
  • ISM5939 demonstrated superior potency with IC50 values of 0.63 nM against cGAMP degradation and showed synergistic effects when combined with anti-PD-1 therapy and chemotherapy in preclinical studies.
  • The compound exhibits a wider therapeutic index compared to direct STING agonists, avoiding systemic cytokine release and T-cell apoptosis while effectively enhancing antitumor immunity in multiple solid tumor types.

Novartis Invests in Aging Research: A $550 Million Bet on the Future of Drug Development

AI
• Novartis has partnered with BioAge Labs in a deal worth up to $550 million, gaining access to one of the world's largest human longevity datasets to develop treatments for age-related diseases.
• The pharmaceutical giant established its Diseases of Aging and Regenerative Medicine (DARe) research group in 2023, focusing on understanding biological drivers of aging to potentially treat multiple age-related conditions simultaneously.
• With the global population of people over 60 expected to double to 2.1 billion by 2050, the market for geriatric medicines is projected to reach $222.5 billion by 2030, making aging research increasingly lucrative.

AI Transforms Real-World Data into Regulatory-Grade Evidence for Ophthalmology Research

AI
  • Regulatory agencies like FDA and EMA are increasingly incorporating real-world data into clinical research and regulatory decision-making, recognizing its potential to enhance drug development and improve patient outcomes.
  • AI technologies are playing a crucial role in transforming unstructured ophthalmology data from sources like electronic health records into standardized, regulatory-grade evidence that meets stringent quality requirements.
  • Verana Health's VeraQ® population health data engine is converting raw data from the American Academy of Ophthalmology IRIS® Registry into research-ready datasets that can support regulatory decisions for conditions like cataracts and neovascular age-related macular degeneration.

MindHYVE.ai Partners with Islamabad Diagnostic Centre to Deploy AGI-Powered Diagnostic Intelligence Across Pakistan

AI
  • MindHYVE.ai, a U.S.-based artificial general intelligence company, has signed a memorandum of understanding with Islamabad Diagnostic Centre to deploy AGI-powered diagnostic agents across Pakistan's healthcare system.
  • The collaboration will introduce Chiron and Ava-AutoNarrator, two proprietary AGI agents designed to enhance decision precision, speed, and reproducibility in radiology and laboratory services.
  • The three-phase rollout strategy begins with pilot deployment at flagship centers in Islamabad and Lahore, followed by expansion across 5-7 IDC locations, and ultimately scaling to IDC's 130+ branches nationwide.
  • All systems will operate under MindHYVE.ai's Ethical AGI Protocol, incorporating human-in-the-loop validation, encrypted patient data pathways, and regulatory compliance with DRAP and PNAC oversight.

Fujitsu and THERS Successfully Deploy AI to Accelerate Clinical Trial Recruitment and Combat Drug Loss in Japan

AI
  • Fujitsu and Tokai National Higher Education and Research System (THERS) have completed successful field trials using generative AI to structure clinical data, achieving approximately 90% accuracy with 1,800 breast surgery patient records.
  • The AI-powered approach identified 42 potential clinical trial candidates with 27 being actually eligible, potentially reducing patient selection time by approximately one-third and accelerating clinical research processes.
  • This initiative directly addresses Japan's "drug loss" problem—the lack of availability of drugs used overseas due to stringent local approval requirements—by streamlining clinical trials and improving real-world data utilization.

Flatiron Health to Present 14 Real-World Oncology Data Studies at ASCO 2025

AIReal World EvidenceOncology
  • Flatiron Health will showcase 14 abstracts at ASCO 2025, leveraging AI and real-world data from over five million cancer patients to generate actionable evidence for improved cancer care.
  • Key research includes the largest real-world study of ctDNA testing in early-stage breast cancer, an assessment of racial disparities in PSMA-PET scan usage for prostate cancer patients, and innovations in clinical trial enrollment.
  • The company's research aligns with ASCO's 2025 theme "Driving Knowledge to Action: Building a Better Future" by using advanced machine learning and AI to transform patient experiences into knowledge for a more connected oncology ecosystem.

New-Onset Diabetes Emerges as Early Warning Signal for Pancreatic Cancer Detection

AIPrecision Medicine
  • New-onset diabetes (NOD) affects approximately 1% of pancreatic cancer cases and may serve as an early indicator of pancreatic ductal adenocarcinoma, with elderly NOD patients facing six to eight times higher cancer risk compared to the general population.
  • Research reveals that metabolic changes associated with pancreatic cancer-related diabetes begin occurring 1.5-2 years before cancer diagnosis, with notable increases in blood glucose and weight loss observed 6-18 months prior to clinical presentation.
  • Scientists have identified 75 proteins associated with pancreatic cancer-related diabetes and discovered potential biomarkers including specific miRNA profiles and elevated serum levels of galectin-3 and S100A9 that could distinguish cancer-associated diabetes from typical type 2 diabetes.
  • The ENDPAC risk prediction model and emerging AI-based screening strategies show promise for early detection, while comprehensive biobanking initiatives are being established to support biomarker discovery in ethnically diverse populations.

NIH Scientists Develop Novel Surgical Technique to Enhance Cell Therapy for Dry Age-Related Macular Degeneration

AI
  • NIH researchers have developed a new surgical technique that enables implantation of multiple tissue grafts in the retina, potentially expanding treatment options for dry AMD.
  • The innovative surgical clamp maintains eye pressure during sequential insertion of two tissue patches while minimizing surrounding tissue damage.
  • Animal studies demonstrated that retinal pigment epithelial cell grafts promoted photoreceptor survival and regenerated the choriocapillaris blood vessel network.
  • The findings build upon an ongoing first-in-human clinical trial of patient-derived RPE grafts for dry AMD treatment.

Bayer Launches Centafore: New Imaging Core Lab to Enhance Clinical Trial Imaging and SaMD Development

OncologyAI
  • Bayer has launched Centafore, an Imaging Contract Research Organization (iCRO) with over 25 years of experience supporting more than 200 clinical trials globally.
  • Centafore offers comprehensive imaging services spanning from early research through Phase IV trials and Software as a Medical Device development across multiple therapeutic areas including oncology, cardiovascular, and CNS.
  • The new imaging solution provider leverages an extensive network of imaging professionals across 50+ countries, aiming to enhance trial outcomes and support informed decision-making in drug development.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.